This program features a combination of case-based presentations and literature review to summarize the antiplatelet needs of patients with cardiogenic shock and ACS. Faculty discusses several technical issues associated with oral and nonoral antiplatelets agents, and the program will underscore what is known about cangrelor, a parenteral, fast-acting, reversible P2Y12 inhibitor.

• Case Presentation
• Pharmacodynamics of Novel Antiplatelet Agents
• Anti-Platelet Concerns in Cardiogenic Shock: The Case for Parenteral Use
• Cangrelor: Trial Data, Indications, and Contraindications
• Case Presentation
• Panel Discussion

PROGRAM CHAIRS

• Bhatt, Deepak. Principal Investigator for a Research Study: Abbott (St. Jude), Afimmune, Amarin, Amgen, AstraZeneca, Boehringer Ingel-heim, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Idorsia, Ironwood, Lilly, Medtronic, Pfizer, Sanofi Aventis, The Medicines Company.
• Naidu, Srihari. No relevant relationships with commercial interests to disclose.

FACULTY

• Butala, Neel. No relevant relationships with commercial interests to disclose.
• Henry, Timothy. No relevant relationships with commercial interests to disclose.
• Mehran, Roxanna. Consulting: Abiomed, Janssen Scientific Affairs, Sanofi, Roivant Services, Siemens Medical Solutions, Medscape/WebMD, Boston Scientific Corp, The Medicines Company. Speakers Bureau: Medtelligence (Janssen Scientific Affairs). Advisory Board/Board Member: Medtelligence (Janssen Scientific Affairs), PLx Opco/PLx Pharma Inc. Ownership Interests: Stocks, Stock Options: Clarer Medical, Elixir Medical. Principal Investigator for a Research Study, Abbott (St. Jude), Bayer, CSL Behring, DSI, Medtronic, Chiesi USA, Inc. Patent Holder/Intellectual Property Rights: AstraZeneca
• Osborne, Eric. Abbott Vascular, Consulting. Dyad Medical, Advisory Board/Board Member. Rathakrishnan, Bharath Gopal. No relevant relationships with commercial interests to disclose.

SCAI STAFF

• Bartel, Robert. No relevant relationships with commercial interests to disclose. 
• Porter, Laura Daigle. No relevant relationships with commercial interests to disclose.

Accreditation Statement: 
The Society for Cardiovascular Angiography and Interventions is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation:
The Society for Cardiovascular Angiography and Interventions designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

To obtain credit please complete the evaluation in its entirety.

Antiplatelet Considerations in Cardiogenic Shock is supported by an unrestricted education grant from Chiesi.

SCAI’s Independent Content: 
As a provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME), it is the Society’s policy to ensure balance, independence, objectivity, and scientific rigor in all its activities. All participating faculty, course directors, planning committee members and staff are required to disclose to SCAI any relevant financial relationships. SCAI identifies relevant conflicts of interest and resolves them before the activity begins.

Planning Process:
SCAI activities are developed by the SCAI Planners prior to and independent of commercial support. Members of the Planning Committee reviewed and approved this activity, and those with relevant conflicts of interest recused themselves. Members of SCAI’s Continuing Medical Education Oversight Committee, clinicians in the field of cardiac catheterization and angiography, reviewed all educational materials and verified that the materials are fair, accurate, and free of commercial bias. 
Content Validation Statement: 
SCAI accepts the following Content Validation Statements and expects all persons involved in its professional education activities to abide by these statements for clinical care recommendations. All clinical and pharmacological recommendations are based on evidence accepted within the medical profession as adequate jurisdiction for their indications and contradictions in patient care. All research referenced to support or justify patient care recommendations conforms to accepted standards of experimental design, data collection and analysis. SCAI encourages faculty to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

© 2019 Society for Cardiovascular Angiography and Interventions (SCAI). All rights reserved.